NASDAQ$SUPN
Supernus Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported first quarter financial results, highlighted by a 16% increase in total revenues and FDA approval of Qelbree for adults.
Supernus Pharmaceuticals reported a strong first quarter in 2022, with a 16% increase in total revenues to $152.5 million compared to Q1 2021. Net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively. The FDA approved Qelbree for ADHD treatment in adults, and Qelbree prescriptions increased by 38% compared to Q4 2021.
- Total revenues for Q1 2022 reached $152.5 million, a 16% increase year-over-year.
- Net earnings for Q1 2022 were $25.6 million, with a diluted EPS of $0.43.
- Qelbree prescriptions continued to grow, reaching 47,324 in Q1 2022, a 38% increase compared to Q4 2021.
- The FDA approved Qelbree for the treatment of ADHD in adults.
Headline financials
Revenue & EPS history
Supernus · Revenue · Quarterly
$153M
Revenue by segment
Supernus · $90.3M total across 2 segments · Q1 2022
- Trokendi XR$62.8M+87465081.1%69.5%
- Oxtellar XR$27.5M+100364863.5%30.5%
Forward guidance
Supernus Pharmaceuticals reiterates its full-year 2022 financial guidance, with total revenues expected to be between $640 million and $680 million and operating earnings between $20 million and $40 million.
Tailwinds
- Total revenues are projected to be between $640 million and $680 million.
- Combined R&D and SG&A expenses are expected to be between $460 million and $490 million.
- Operating earnings are projected to be between $20 million and $40 million.
- Non-GAAP operating earnings are projected to be between $130 million and $165 million.
- Company is preparing for the commercial launch of SPN-830 in the first quarter of 2023, assuming timely approval by the FDA.
Headwinds
- Operating earnings include amortization of intangible assets and contingent consideration expense (gain).
- Decrease in cash and cash equivalents primarily due to milestone payments and transition expense payments.
- Amortization of acquired intangible assets from the Adamas Acquisition.
- The Company will continue to work closely with the FDA as it reviews the New Drug Application (NDA) resubmission for SPN-830
- An open-label Phase II clinical study of SPN-817 in patients with treatment-resistant seizures is expected to start in the second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.1%
Avg return
30 days after
48%
27 / 56 earnings
Positive
+22.3%
Q3 2020
Best reaction
-29.9%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +6.1% | -8.1% | |
| Q4 2025 | +7.9% | +0.7% | +0.1% | |
| Q3 2025 | -16.9% | -20.4% | -19.9% | |
| Q1 2025 | -4.6% | -0.9% | +2.2% | |
| Q4 2024 | -2.7% | -3.3% | -1.6% | |
| Q3 2024 | +2.3% | +7.7% | +9.4% | |
| Q2 2024 | +14.3% | +15.0% | +23.1% | |
| Q1 2024 | -3.7% | -4.7% | -15.7% | |
| Q4 2023 | +5.4% | +5.1% | +15.6% | |
| Q3 2023 | +9.6% | +14.5% | +12.8% | |
| Q2 2023 | -5.3% | -1.1% | -6.8% | |
| Q1 2023 | -0.2% | -7.2% | -3.3% | |
| Q4 2022 | +3.4% | +4.8% | -4.5% | |
| Q3 2022 | -5.9% | +0.9% | +2.5% | |
| Q2 2022 | +0.4% | -3.1% | +7.4% | |
| Q1 2022 | -6.0% | -2.5% | +2.7% | |
| Q4 2021 | -3.1% | -8.7% | -16.5% | |
| Q3 2021 | +5.0% | +11.6% | +1.1% | |
| Q2 2021 | -1.1% | -4.3% | +2.1% | |
| Q1 2021 | -2.7% | -2.5% | -0.7% | |
| Q4 2020 | -13.2% | -12.1% | -11.3% | |
| Q3 2020 | +22.3% | +28.4% | +18.5% | |
| Q2 2020 | -6.0% | -12.5% | -9.7% | |
| Q1 2020 | +4.7% | +4.3% | +7.8% | |
| Q4 2019 | -18.5% | -6.6% | -17.7% | |
| Q3 2019 | -29.9% | -23.6% | -22.8% | |
| Q2 2019 | -11.8% | -11.5% | -14.0% | |
| Q1 2019 | -7.0% | -5.0% | -20.3% | |
| Q4 2018 | +12.8% | +2.2% | -0.6% | |
| Q3 2018 | +8.4% | +8.6% | -2.8% | |
| Q2 2018 | -8.1% | -12.9% | -13.6% | |
| Q1 2018 | +6.3% | +26.5% | +20.2% | |
| Q4 2017 | +0.0% | +1.9% | +17.7% | |
| Q3 2017 | -13.4% | -11.4% | -13.3% | |
| Q2 2017 | +3.1% | +4.1% | +17.2% | |
| Q1 2017 | +0.0% | +4.2% | +28.7% | |
| Q4 2016 | -2.4% | -1.1% | +9.5% | |
| Q3 2016 | +5.1% | +10.2% | +11.1% | |
| Q2 2016 | +3.2% | +4.0% | -0.9% | |
| Q1 2016 | -5.7% | — | — | |
| Q4 2015 | +7.8% | — | — | |
| Q3 2015 | +6.0% | — | — | |
| Q2 2015 | -8.9% | — | — | |
| Q1 2015 | -7.1% | — | — | |
| Q4 2014 | +11.1% | — | — | |
| Q3 2014 | +4.1% | — | — | |
| Q2 2014 | +7.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +9.8% | — | — | |
| Q3 2013 | +9.5% | — | — | |
| Q2 2013 | +6.8% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | -22.6% | — | — | |
| Q3 2012 | +2.8% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q1 2012 | -5.9% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro